---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-229767"
form_type: "8-K"
ticker: "BLCO"
cik: "0001860742"
company_name: "Bausch & Lomb Corp"
filed_at: "2023-09-06T23:59:59+00:00"
generated_at: "2026-06-10T23:37:41.922231+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bausch + Lomb provides financials for Novartis XIIDRA acquisition; $1.75B upfront plus $750M milestones

## Summary
- Acquisition of XIIDRA (lifitegrast) and certain ophthalmology assets from Novartis for $1.75B upfront and up to $750M milestone payments.
- Closing expected at or around end of September 2023, subject to customary conditions.
- Acquired assets had net revenue of $487M in 2022 and $468M in 2021, with total comprehensive shortfall of $384M in 2022.
- Net assets acquired were $2.065B as of Dec 31, 2022, including $2.138B intangible asset.

## SEC filing metadata
- accession: 0001193125-23-229767
- form_type: 8-K
- ticker: BLCO
- cik: 0001860742
- company_name: Bausch & Lomb Corp
- filed_at: 2023-09-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860742/000119312523229767/0001193125-23-229767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860742/000119312523229767/d548500d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-229767
- JSON: https://secwatch.observer/filing/0001193125-23-229767.json
- Plain text: https://secwatch.observer/filing/0001193125-23-229767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.